Fresenius SE & Co KGaA, a company specializing in pharmaceuticals, medical devices, and equipment for clinical and home hospitalization, has received a "Buy" rating from UBS.

The company's sales are primarily driven by its hospital administration and engineering segment, which accounts for 64.3% of total sales. This segment includes hospital management services and the production of medical equipment.

Fresenius Kabi, representing the perfusion and clinical nutrition segment, contributes 35.7% of sales. This segment focuses on parenteral and oral nutrition products, transfusion equipment, and home medical assistance services.

Geographically, the majority of Fresenius SE's sales are in Europe (72.4% of total sales), followed by North America (12.3%), Asia-Pacific (7.3%), Latin America (6.4%), and Africa (1.6%). The company's diverse portfolio and strong market presence in Europe position it favorably within the healthcare sector, as it continues to meet the growing demand for medical services and products.